Biomea Fusion, Inc. (BMEA)

Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

Biomea Fusion Announces Proposed Public Offering of Securities

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

Biomea Fusion to Participate in Upcoming Investor Conferences

Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights